A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2020

Primary Completion Date

August 5, 2020

Study Completion Date

August 5, 2020

Conditions
Autoimmune Hemolytic AnemiaImmune Thrombocytopenia
Interventions
DRUG

KZR-616

Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks

Trial Locations (22)

10467

KZR Research Site, The Bronx

27834

KZR Research Site, Greenville

32224

KZR Research Site, Jacksonville

33014

KZR Research Site, Miami Lakes

33612

KZR Research Site, Tampa

43210

KZR Research Site, Columbus

44195

KZR Research Site, Cleveland

55454

KZR Research Site, Minneapolis

55455

KZR-616 Research Site, Rochester

61615

KZR Research Site, Peoria

77598

KZR Research Site, Webster

90007

KZR Research Site, Los Angeles

94143

KZR Research Site, San Francisco

02114

KZR Research Site, Boston

07960

KZR Research Site, Morristown

Unknown

KZR Research Site, Woolloongabba

KZR Research Site, Bologna

KZR Research Site, Genova

KZR Research Site, Krakow

KZR Research Site, Poznan

KZR Research Site, Moscow

KZR Research Site, Saint Petersburg

Sponsors
All Listed Sponsors
lead

Kezar Life Sciences, Inc.

INDUSTRY

NCT04039477 - A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP | Biotech Hunter | Biotech Hunter